Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer.

Delivery of therapeutic agents to bone is crucial in several diseases such as osteoporosis, Paget's disease, myeloproliferative diseases, multiple myeloma as well as skeletal metastasizing cancers. Prevention of cancer growth and lowering the cancer induced bone resorption is important in the treatment of bone metastasizing cancers. Keeping in mind the low diffusivity and availability of cell surface targets on cancer cells, we designed a targeted system to deliver chemotherapeutic agents to the bone microenvironment as an approach to tissue targeting using alendronate (Aln). We co-encapsulated curcumin and bortezomib in the PLGA nanoparticles to further enhance the therapeutic efficiency and overall clinical outcome. These multifunctional nanoparticles were characterized for particle size, morphology and drug encapsulation. The particles were spherical with smooth surface and had particle size of 235 ± 70.30 nm. We validated the bone targeting ability of these nanoparticles in vitro. Curcumin and bortezomib are known to have synergistic effect in inhibition of growth of cancer; however there was no synergism in the anti-osteoclastogenic activity of these agents. Surprisingly, curcumin by itself had significant inhibition of osteclastogenic activity. In vivo non-invasive bioimaging showed higher localization of Aln-coated nanoparticles to the bone compared to control groups, which was further confirmed by histological analysis. Aln-coated nanoparticles protected bone resorption and decreased the rate of tumor growth as compared to control groups in an intraosseous model of bone metastasis. Our data show efficient attachment of Aln on the surface of nanoparticles which could be used as a drug carrier for preferential delivery of multiple therapeutic agents to bone microenvironment.

[1]  S. Fowler,et al.  Nile red: a selective fluorescent stain for intracellular lipid droplets , 1985, The Journal of cell biology.

[2]  P. Richardson,et al.  Bortezomib: proteasome inhibition as an effective anticancer therapy. , 2005, Future oncology.

[3]  S. Nie,et al.  Therapeutic Nanoparticles for Drug Delivery in Cancer Types of Nanoparticles Used as Drug Delivery Systems , 2022 .

[4]  J. Vishwanatha,et al.  Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. , 2009, Anticancer research.

[5]  M. Pirmohamed,et al.  Phase I Clinical Trial of Oral Curcumin , 2004, Clinical Cancer Research.

[6]  J. Vishwanatha,et al.  Polymeric nanoparticles for sustained down-regulation of annexin A2 lead to reduction in proliferation and migration of prostate cancer cells , 2007 .

[7]  M. R. Kumar,et al.  Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[8]  B. Aggarwal,et al.  Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis. , 2004, Journal of immunology.

[9]  B. Kim,et al.  Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells , 2008, Molecular oncology.

[10]  G. Mundy Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities , 2002, Nature Reviews Cancer.

[11]  Sung‐Wook Choi,et al.  Design of surface-modified poly(D,L-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[12]  R. Russell,et al.  Determinants of structure–function relationships among bisphosphonates , 2007 .

[13]  G. Stein,et al.  A Proteasome Inhibitor, Bortezomib, Inhibits Breast Cancer Growth and Reduces Osteolysis by Downregulating Metastatic Genes , 2010, Clinical Cancer Research.

[14]  J. Pollard,et al.  Microenvironmental regulation of metastasis , 2009, Nature Reviews Cancer.

[15]  G. Storm,et al.  Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro. , 2007, International journal of pharmaceutics.

[16]  I. Chourpa,et al.  Optimization of iron oxide nanoparticles encapsulation within poly(d,l-lactide-co-glycolide) sub-micron particles. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[17]  M. Ferrari Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[18]  E. Schleicher,et al.  The Chemopreventive Polyphenol Curcumin Prevents Hematogenous Breast Cancer Metastases in Immunodeficient Mice , 2006, Cellular Physiology and Biochemistry.

[19]  J. Kopeček,et al.  Bone-targeting macromolecular therapeutics. , 2005, Advanced drug delivery reviews.

[20]  B. Aggarwal,et al.  Curcumin (Diferuloylmethane) Inhibits Receptor Activator of NF-κB Ligand-Induced NF-κB Activation in Osteoclast Precursors and Suppresses Osteoclastogenesis1 , 2004, The Journal of Immunology.

[21]  B. Aggarwal,et al.  Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model (Molecular Cancer Therapeutics (2009) 8, (959-970)) , 2009 .

[22]  G. H. Nancollas,et al.  Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. , 2006, Bone.

[23]  P. Clézardin,et al.  Mechanisms of Bisphosphonate Effects on Osteoclasts, Tumor Cell Growth, and Metastasis , 2002, American journal of clinical oncology.

[24]  J. Kopeček,et al.  Targeting polymer therapeutics to bone. , 2012, Advanced drug delivery reviews.

[25]  S. Avnet,et al.  Biocompatibility of poly(D,L-lactide-co-glycolide) nanoparticles conjugated with alendronate. , 2008, Biomaterials.

[26]  B. Aggarwal,et al.  Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model , 2009, Molecular Cancer Therapeutics.

[27]  W. Dalton,et al.  The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance , 2008, Clinical Cancer Research.

[28]  J. Vishwanatha,et al.  Surface functionalization of PLGA nanoparticles by non-covalent insertion of a homo-bifunctional spacer for active targeting in cancer therapy , 2011, Nanotechnology.

[29]  V. Ratanatharathorn,et al.  Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology. , 2009, Journal of palliative medicine.

[30]  G. Hortobagyi,et al.  Overview of resistance to systemic therapy in patients with breast cancer. , 2007, Advances in experimental medicine and biology.

[31]  Murali Mohan Bommana,et al.  The formulation, characterization and in vivo evaluation of a magnetic carrier for brain delivery of NIR dye , 2010, Nanotechnology.

[32]  M. Pirmohamed,et al.  Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. , 2001, Clinical Cancer Research.

[33]  S. Knapp,et al.  The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. Angelucci,et al.  Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases. , 2010, Current cancer drug targets.

[35]  H. Uludaǧ,et al.  Bisphosphonate-coated BSA nanoparticles lack bone targeting after systemic administration , 2010, Journal of drug targeting.

[36]  M. Ferrer,et al.  Enhanced emission of nile red fluorescent nanoparticles embedded in hybrid sol-gel glasses. , 2005, The journal of physical chemistry. B.

[37]  A. Lipton Implications of bone metastases and the benefits of bone-targeted therapy. , 2010, Seminars in oncology.

[38]  Robert Langer,et al.  Nanoparticle technologies for cancer therapy. , 2010, Handbook of experimental pharmacology.

[39]  Tayyaba Hasan,et al.  Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited. , 2009, Molecular pharmaceutics.

[40]  J. Vishwanatha,et al.  A sustained release formulation of chitosan modified PLCL:poloxamer blend nanoparticles loaded with optical agent for animal imaging , 2011, Nanotechnology.